Research on novel technologies can bring robust therapeutic protocols for orphan diseases
Mumbai, August 21, 2021:
The research on novel technologies can help to identify robust therapeutic protocols for orphan diseases, stated Dr Pradeep Mahajan, regenerative medicine researcher, StemRx Bioscience Solutions Pvt. Ltd., Mumbai.
Dr Mahajan added, “Novel therapies should be researched to suit the ever-evolving pathologies. This is where regenerative medicine (RM), cell-based therapy (CBT), and immunotherapy have gradually emerged as promising modalities. The principle lies in understanding molecular mechanisms and harnessing the natural healing potential of the body to treat various diseases. Considering that the human body (young or old) is a direct source of stem cells, immune cells, and growth factors, RM/immunotherapy may be considered effective therapeutic modalities.”
These cells and growth factors work to ensure balance/homeostasis in the body; therefore, perform several functions like controlling inflammation, regulating the immune system, enhancing the functions of different cells, etc. Thus, providing these cells in the required quantity in the required area (of disease) at the correct time will enhance regeneration in that area as well as improve overall healing.
To address the education and training gaps in this new area of regenerative medicine, the Maharashtra University of Health Sciences, Nashik granted first affiliations to conduct a fellowship course in regenerative medicine and stem cell-based therapies on research basis at Dr Mahajan’s Hospital & StemRx Bioscience Solution Pvt Ltd, Navi Mumbai.
The fellowship course has been designed to ensure that qualified individuals get the required theoretical training as well as practical exposure to learn the intricacies of research in the field of regenerative medicine (RM).
Dr Mahajan stated, “Through this fellowship course, the candidates will be able to pursue their own research in this field and contribute to the ever-increasing need for novel therapeutic technologies.”
This 2-year fellowship program includes theory and practical training in the science of RM, regulatory aspects, ethics, emerging technologies in cell-based therapies, pre-clinical studies, and mesenchymal stem cell isolation and transplantation, among other topics. MBBS, MD/MS/M.Ch,/DM/DNB qualified surgeons/physicians/super specialists, foreigners with or postgraduate degrees equivalent to and recognized by the Medical Council of India are the candidates eligible for this fellowship.
StemRx also added that it has collaborated with Amity Institute of Biotechnology to provide backup for clinical research in the field of translational medicine. The institute trains students in the different aspects of RM and CBT for which StemRxwill provide clinical and laboratory support.
The collaboration is important to improve the reach and opportunities for students and professionals to obtain all-round knowledge in the field of RM and CBT.
StemRx Bioscience aims to set the standard in regenerative medicine and cell based therapy through research and clinical excellence and responsiveness to the needs of every patient. PharmaBiz